Clinical Trial

Staphylococcus Aureus Network Adaptive Platform Trial

Study acronym: SNAP
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is an International Multi-Centered Randomised Adaptive Platform Clinical Trial to evaluate a range of interventions to reduce mortality for patients with Staphylococcus Aureus bacteraemia (SAB).
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2021-11-23; most recent amendment 2026-04-29.
Status change: Not Yet Recruiting → Recruiting 2022-02-23
Trial Details
NCT Number NCT05137119
Lead Sponsor University of Melbourne
Collaborators: Berry Consultants, McGill University Health Centre/Research Institute of the McGill University Health Centre, Menzies School of Health Research, Aotearoa Clinical Trials, Queensland University of Technology, Sunnybrook Health Sciences Centre, Tan Tock Seng Hospital, Telethon Kids Institute, The Peter Doherty Institute for Infection and Immunity, The University of Queensland, UMC Utrecht, Radboud University Medical Center, King's College London, Rambam Health Care Campus, University College, London, The Methodist Hospital Research Institute
Conditions Staphylococcus Aureus Bacteremia
Enrollment 8,000 participants
Start Date 2022-02-16
Primary Completion 2028-12-01 (estimated)
Study Completion 2028-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-06